The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study

Hdl Handle:
http://hdl.handle.net/10144/619175
Title:
The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
Authors:
Abongomera, C; Diro, E; de Lima Pereira, A; Buyze, J; Stille, K; Ahmed, F; van Griensven, J; Ritmeijer, K
Journal:
PLoS Neglected Tropical Diseases
Abstract:
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.
Publisher:
Public Library of Science
Issue Date:
25-May-2018
URI:
http://hdl.handle.net/10144/619175
DOI:
10.1371/journal.pntd.0006527
PubMed ID:
29799869
Submitted date:
2018-06-04
Language:
en
ISSN:
1935-2735
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorAbongomera, Cen
dc.contributor.authorDiro, Een
dc.contributor.authorde Lima Pereira, Aen
dc.contributor.authorBuyze, Jen
dc.contributor.authorStille, Ken
dc.contributor.authorAhmed, Fen
dc.contributor.authorvan Griensven, Jen
dc.contributor.authorRitmeijer, Ken
dc.date.accessioned2018-06-12T14:57:44Z-
dc.date.available2018-06-12T14:57:44Z-
dc.date.issued2018-05-25-
dc.date.submitted2018-06-04-
dc.identifier.citationThe initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study. 2018, 12 (5):e0006527 PLoS Negl Trop Disen
dc.identifier.issn1935-2735-
dc.identifier.pmid29799869-
dc.identifier.doi10.1371/journal.pntd.0006527-
dc.identifier.urihttp://hdl.handle.net/10144/619175-
dc.description.abstractNorth-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.en
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen
dc.titleThe initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort studyen
dc.identifier.journalPLoS Neglected Tropical Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.